Ph 1b trial of elraglusib, retifanlimab, and mFOLFIRINOX combo as 1L therapy in advanced pancreatic adenocarcinoma initiated

“We believe the combination of elraglusib with retifanlimab and mFOLFIRINOX represents a novel and mechanistically compelling strategy to address unmet needs in advanced pancreatic adenocarcinoma,” said Daniel Schmitt, President & Chief Executive Officer of Actuate. “The collaboration with UPMC Hillman Cancer Center and Incyte enables us to explore new synergistic opportunities for patients who have not yet received systemic therapy and builds on the momentum of our ongoing clinical programs. The study further allows us to assess ways to optimize elraglusib’s potential through a complementary multi-agent approach designed to enhance both efficacy and durability of response.”  

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib